Manufacturer copay assistance · Darzalex Faspro (J9144) · Janssen (Johnson & Johnson)
Eligible patients pay as… · Maximum benefit Up to $26,000/year (some sources cite $15,000 — varies by program structure) · Covers Darzalex Faspro drug cost — does NOT cover infusion administration
Published terms from the manufacturer. Per-patient eligibility is confirmed at enrollment.
This manufacturer program excludes government insurance. Foundation disease funds are the route instead — status shown as of each fund's last verification.
Run a benefits estimate for Darzalex Faspro — the program's cap applies against the patient share CareCost calculates.
Yes — Janssen CarePath Savings Program (Darzalex Faspro) from Janssen (Johnson & Johnson). Eligible patients pay as little as $5 per dose. Commercial insurance is required; Medicare and Medicaid patients are not eligible.
Eligible patients pay as little as $5 per dose Maximum benefit: Up to $26,000/year (some sources cite $15,000 — varies by program structure). Covers Darzalex Faspro drug cost — does NOT cover infusion administration
Accepted insurance: commercial. Not eligible: medicare, medicaid, tricare, va, government.